As research continues to elucidate the intricate mechanisms of SHP2’s involvement in the PD-1 pathway, novel therapeutic strategies that harness its potential could pave the way for more effective ICI resistance therapies, offering renewed hope for cancer patients facing limited treatment options. This evidence concerns the gene PTPN11 and cancer.